导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.43% | 860/2676 |
| 近一周 | -1.09% | 896/3004 |
| 近一月 | -6.84% | 2325/2984 |
| 近一季 | 12.72% | 92/2896 |
| 近半年 | 2.76% | 556/2746 |
| 近一年 | -5.80% | 1761/2519 |
| 近两年 | 38.02% | 1198/1796 |
| 近三年 | 5.55% | 1086/1340 |
| 成立以来 | 41.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.24% 1595/4961 |
-2.04% 3382/5312 |
- - |
- - |
| 2025 | 16.00% 2498/4813 |
4.92% 860/3635 |
3.25% 1082/4076 |
16.78% 2604/4524 |
-8.31% 3899/4813 |
| 2024 | -13.37% 2406/3463 |
-10.83% 2385/2808 |
-7.08% 2054/3014 |
13.37% 2181/3129 |
-7.77% 2795/3463 |
| 2023 | -6.18% 820/2656 |
2.00% 1467/2280 |
-4.13% 1063/2385 |
-3.28% 886/2515 |
-0.81% 257/2655 |
| 2022 | -24.51% 1224/2207 |
-13.51% 771/1919 |
-0.93% 1661/2016 |
-17.54% 1611/2113 |
6.85% 341/2208 |
| 2021 | -4.76% 958/1822 |
1.44% 254/1255 |
13.59% 283/1330 |
-11.38% 1265/1466 |
-6.73% 1546/1822 |
| 2020 | 67.36% 85/1250 |
15.51% 4/1028 |
37.51% 11/1067 |
-0.46% 1056/1164 |
5.85% 771/1184 |
| 2019 | 60.10% 52/1092 |
31.92% 185/754 |
0.78% 159/804 |
13.84% 21/850 |
5.78% 676/918 |
| 2018 | -20.39% 193/834 |
- - |
- - |
- - |
-18.47% 656/691 |
| 2017 | 4.50% 415/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富国中证医药主题指数增强A VS. 长安沪深300非周期A(740101) |